Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Nvidia Develops New Location-Verification Technology for AI Chips 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
SAN DIEGO, Nov. 08, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that the company will participate in the Stifel 2017 Healthcare Conference in New York, NY.
The Company will be presenting at 9:30 AM Eastern on Wednesday, November 15, 2017. A live webcast of the presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
